10-methyl spiro(4.5)dec-6-en-6-carboxylic acid profile

You're asking about **10-methylspiro[4.5]dec-6-en-6-carboxylic acid**.

This molecule is not a well-known or commonly studied compound. It's likely a synthetic molecule created for specific research purposes, and it's hard to determine its significance without further context.

**Here's why it's difficult to provide a clear answer:**

* **Lack of information:** You haven't provided any information about the research context or the potential applications of this compound.
* **Specificity:** The name itself implies a very specific structure with a methyl group, a spirocyclic system, a double bond, and a carboxylic acid group. This suggests a particular type of molecule designed for a particular research purpose.

**To understand the importance of 10-methylspiro[4.5]dec-6-en-6-carboxylic acid, you'd need to know:**

* **The research area it's being studied in:** Is it related to drug discovery, materials science, organic synthesis, or another field?
* **The specific research questions it's addressing:** What properties or reactions are being investigated?
* **The potential applications:** Could it be a precursor for other compounds, a potential therapeutic agent, or a model system for studying specific chemical reactions?

**To find more information, I recommend:**

* **Searching for specific publications:** Look for research papers that mention this compound by name.
* **Consulting with a chemist:** If you have access to a chemistry expert, they might be able to provide more insight based on the structure and potential applications.

Without more details, it's impossible to say with certainty why this specific molecule is important for research.

10-methyl spiro(4.5)dec-6-en-6-carboxylic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	131526
MeSH ID	M0186072

Synonym
10-methyl spiro(4.5)dec-6-en-6-carboxylic acid
132603-09-9
spiro(4.5)dec-6-ene-6-carboxylic acid, 10-methyl-
msdc
6-methylspiro[4.5]dec-9-ene-10-carboxylic acid
10-methylspiro[4.5]dec-6-ene-6-carboxylic acid
DTXSID30927731

Excerpt	Reference	Relevance
" No network meta-analysis (NMA) analyzes the adverse events of antifibrotic drugs for NAFLD."	( Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Feng, P; Lei, H; Lei, R; Li, Y; Xie, F; Xiong, Q; Yao, C, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	7 (87.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (12.50%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (75.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.6	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.41	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
2,4-thiazolidinedione thiazolidine-2,4-dione: structure in first source. 1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.	2.41	1	thiazolidenedione
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	2.41	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.6	1	copper group element atom; elemental gold
sesquiterpenes [no description available]	1.97	1
cenicriviroc cenicriviroc: an inhibitor of HIV-1. cenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH).	3.7	1	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist
liraglutide [no description available]	3.7	1	lipopeptide; polypeptide	glucagon-like peptide-1 receptor agonist; neuroprotective agent

Condition	Relationship Strength	Studies	Trials
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.41	1	0
Adverse Drug Event [description not available]	5.47	4	0
Fatty Liver, Nonalcoholic [description not available]	7.03	5	1
Cirrhosis, Liver [description not available]	5.47	4	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	5.47	4	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	5.47	4	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	7.03	5	1
Diabetes Mellitus, Adult-Onset [description not available]	3.99	1	1
Hepatocellular Carcinoma [description not available]	3.99	1	1
Insulin Sensitivity [description not available]	3.99	1	1
Cancer of Liver [description not available]	3.99	1	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	3.99	1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.99	1	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	3.99	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	3.99	1	1
2019 Novel Coronavirus Disease [description not available]	2.6	1	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.6	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.6	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.6	1	0
Carcinoma, Anaplastic [description not available]	2.6	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.6	1	0

10-methyl spiro(4.5)dec-6-en-6-carboxylic acid

Description

Cross-References

Synonyms (7)

Research Excerpts

Toxicity

Research

Studies (8)

Market Indicators

Research Demand Index: 12.15

Study Types